产品
编 号：F741109
分子式：C24H29N3O3S
分子量：439.57
分子式：C24H29N3O3S
分子量：439.57
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
结构图
CAS No: 1120332-55-9
产品详情
生物活性：
NecroX-7 is a potent free radical scavenger and a HMGB1 (high-mobility group box 1) inhibitor. NecroX-7 can be used as an antidote to acetaminophen toxicity. NecroX-7 exerts a protective effect by preventing the release of HMGB1 in ischemia/reperfusion injury. NecroX-7 inhibits the HMGB1-induced release of TNF and IL-6, as well as the expression of TLR-4 and receptor for advanced glycation end products. NecroX-7 can be used graft-versus-host disease (GVHD) research.
体内研究：
NecroX-7 (0-0.3 mg/kg, IV, once injection at 2-d intervals, for 2 weeks) significantly attenuates GVHD-related mortality and inhibits severe tissue damage.NecroX-7 protects mice against lethal GVHD by reciprocal regulation of regulatory T/Th1 cells, attenuating systemic HMGB1 accumulation and inhibiting HMGB1-mediated inflammatory response.Animal Model:Female BALB/c and C57BL/6 mice (Eight-week-old, with GVHD)
Dosage:0.03, 0.1, and 0.3 mg/kg
Administration:IV, once injection at 2-d intervals, for 2 weeks
Result:Observed statistically significant prolonged survival at doses ≥0.1 mg/kg: 30–60% of mice in these treatment groups survived for >50 d. Significantly improved clinical signs and prolonged survival, and the mice showed a reduction in clinical manifestations of acute GVHD, including weight loss, hunched posture, diarrhea, and ruffled fur.
体外研究：
NecroX-7 (0-40 μM, 3-4 d) suppresses activated or proliferating T cells without causing apoptosis.NecroX-7 (0-40 μM) markedly reduces HMGB1 levels in a dose-dependent manner.NecroX-7 inhibits formation of mitochondria-specific ROS/reactive nitrogen species in H9C2 cells and hepatocytes after induction by tert-butyl hydroperoxide or doxorubicin.NecroX-7 increased regulatory T cell numbers, which may be associated with regulation of differentiation signals independent of HMGB1.
NecroX-7 is a potent free radical scavenger and a HMGB1 (high-mobility group box 1) inhibitor. NecroX-7 can be used as an antidote to acetaminophen toxicity. NecroX-7 exerts a protective effect by preventing the release of HMGB1 in ischemia/reperfusion injury. NecroX-7 inhibits the HMGB1-induced release of TNF and IL-6, as well as the expression of TLR-4 and receptor for advanced glycation end products. NecroX-7 can be used graft-versus-host disease (GVHD) research.
体内研究：
NecroX-7 (0-0.3 mg/kg, IV, once injection at 2-d intervals, for 2 weeks) significantly attenuates GVHD-related mortality and inhibits severe tissue damage.NecroX-7 protects mice against lethal GVHD by reciprocal regulation of regulatory T/Th1 cells, attenuating systemic HMGB1 accumulation and inhibiting HMGB1-mediated inflammatory response.Animal Model:Female BALB/c and C57BL/6 mice (Eight-week-old, with GVHD)
Dosage:0.03, 0.1, and 0.3 mg/kg
Administration:IV, once injection at 2-d intervals, for 2 weeks
Result:Observed statistically significant prolonged survival at doses ≥0.1 mg/kg: 30–60% of mice in these treatment groups survived for >50 d. Significantly improved clinical signs and prolonged survival, and the mice showed a reduction in clinical manifestations of acute GVHD, including weight loss, hunched posture, diarrhea, and ruffled fur.
体外研究：
NecroX-7 (0-40 μM, 3-4 d) suppresses activated or proliferating T cells without causing apoptosis.NecroX-7 (0-40 μM) markedly reduces HMGB1 levels in a dose-dependent manner.NecroX-7 inhibits formation of mitochondria-specific ROS/reactive nitrogen species in H9C2 cells and hepatocytes after induction by tert-butyl hydroperoxide or doxorubicin.NecroX-7 increased regulatory T cell numbers, which may be associated with regulation of differentiation signals independent of HMGB1.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备